PhaseV

We are thrilled to share our newly published paper exploring patient outcomes and prognostic factors in colorectal cancer (CRC), leveraging an extensive large real-world dataset of over 700 patients. This study highlights how rich real-world data and advanced analytical methods can reveal meaningful insights into disease progression across diverse patient groups. It was a privilege to collaborate with such a dedicated team on research that enhances our understanding of CRC and brings us closer to improving patient outcomes. walid shalata, Alexander Gluzman, Sofia Man, @Ahron Yehotanat Cohen, Ashraf Abu jama, Itamar Gothelf, Lena Tourkey, alaeddin neime, Ali Abu Juma'a, Sondos Shalata, Ahab Hayadri, Ez el din Abu zeid, Nashat Abu Yasin, Amichay Meirovitz, Alexander Yakobson, Keren Peri-Hanania, M.D. Oshri Machluf, Gal Shoham Levin

How AI is Disturbing Pharma: Read how about the race to harness the potential of AI for faster, more precise drug development, with the FDA leading the regulatory path ahead. Raviv Pryluk

We are excited to present a very small taste of our AdaptV Platform ML capabilities. These capabilities, and many more, are used to power advanced adaptive trial design and optimization, in an intuitive, quick and efficient way. Contact us to learn more and see a full demo info@phasevtrials.com

We are thrilled to announce that Hamza Sheikh is joining our team to head PhaseV’s business development. Hamza brings significant expertise in the implementation of advanced technology for the clinical development market, as well as vast experience leading business development and partnerships in the Pharma and biotech market. He will play a key role in PhaseV’s growth, enabling us to accelerate clinical trial outcomes for more sponsors and more patients

Why choose if you can have it all? By combining open-source and commercial software, sponsors can accelerate drug development, improve clinical trials, and shorten the time to market. Read more about how and why in Elad Berkman's latest article on pharmaphorum

Come hear about our latest work in Bayesian advanced methods applications - both in adaptive trial design and in heterogeneity detection in clinical data, next week at #Bayes2024. Don't miss our CEO Raviv Pryluk, Sr. Data Scientist Oshri Machluf and Head of Business Operations Hamza Sheikh to learn more on how its done and what it next!

Excited to attend #Bayes2024 next week and present the latest advancements and applications in Bayesian clinical trials together with leading speakers from the industry as well as 11 FDA speakers. Make sure to mark PhaseV's Raviv Pryluk and Oshri Machluf's presentations on the agenda, and see you there!

Discover how causal machine learning is revolutionizing clinical trials and advancing drug development in this in-depth interview from DPHARM 2024. Raviv Pryluk, CEO and Co-founder of PhaseV, shares insights on how this cutting-edge technology is overcoming key challenges and improving the accuracy of medical treatments. 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐢𝐧𝐭𝐞𝐫𝐯𝐢𝐞𝐰 𝐡𝐞𝐫𝐞: https://lnkd.in/g7XwqRAB

We do many exciting things, but it's been a while since we were this excited! A first-ever PhaseV podcast episode is out! And you can all hear in just a few minutes how our CARD method is bringing precision medicine to the core of drug development. To read the full paper - check out the first comment. Our incredible team Tzviel Frostig, Oshri Machluf Amitay Kamber Elad Berkman and Raviv Pryluk are to thank for the inspiring work, David Shimon is in charge of the magic that made in into a podcast, and Tal Hochbaum made sure you will all be able to enjoy it. Let us know what you think and what the topic of our next episode should be!

This week at the ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop PhaseV's Elad Berkman and Tzviel Frostig will be presenting our latest groundbreaking work and discussing much more on the topic in our Exhibitor Table #9. Don't miss them!